The purpose of this study was to examine whether oral exposure to aluminum
(Al) can affect the human immune system. Eighteen healthy volunteers (mean
age 42, 28-57 yr) were divided into a test group (9 females, 4 males) and a
referent group (3 females, 2 males). Over 6 weeks, the test subjects inges
ted 10 ml of antacid (aluminum hydroxide, 59 mg Al/ml) three times daily. A
luminum was analyzed in urine before and during the exposure period (ICP-MS
). Blood samples were used for analysis of lymphocyte subpopulations, mitog
en-induced lymphocyte proliferation and in vitro production and circulating
plasma concentrations of immunoglobulin (Ig) A, IgG, IgM, interleukin (IL)
-2 and IL-4. Urinary Al concentration in the test subjects was approximate
ly 10- to 20-fold higher than in the referent group during exposure. This i
ndicates that ingestion of an Al-containing antacid is associated with an A
l absorption far above that originating from food and drinking water. In bo
th referents and test subjects the lymphocyte subpopulations, lymphocyte pr
oliferation and the in vitro Ig and IL production showed similar, time-depe
ndent changes before as well as during the exposure period. No major differ
ences were seen between the referent and test groups regarding the immune p
arameters, except for a slightly smaller CD8+CD45R0+ population (primed cyt
otoxic T-cells), in the exposed individuals as compared to the referents. T
he results also show that subjects on antacid therapy may constitute a suit
able population for studying biological effects of high-dose oral exposure
to Al.